NEW YORK, May 12 Reportlinker.com announces that a new market research report is available in its catalogue:
Autacoids and Related Drugs: Technologies and Global Markets
Advertisement
http://www.reportlinker.com/p0196567/Autacoids-and-Related-Drugs-Technologies-and-Global-Markets.html
THIS REPORT
An overview of autacoids, including such types as histamines and antihistamines, prostaglandins, angiotensin, leukotriens, prostanoids, lipids, nitrogen bases, reactive oxygen species, nitric oxide, and small oligopeptides
Advertisement
Analysis of market trends in related drugs, with data for 2008 and 2009, estimates for 2010, and projections of compound annual growth rates (CAGRs) through 2015
Breakdown of the industry structure with a focus on manufacturers and their market shares
Comprehensive company profiles and detailed patent analyses.
Chapter- 1: INTRODUCTION -- Complimentary
STUDY OBJECTIVES 1
REASONS FOR DOING THIS STUDY 1
INTENDED AUDIENCE 2
SCOPE OF THE STUDY 2
METHODOLOGY 2
INFORMATION SOURCES 2
ABOUT THE AUTHOR 3
RELATED BCC RESEARCH REPORTS 3
BCC ONLINE SERVICES 3
DISCLAIMER 4
Chapter-2: EXECUTIVE SUMMARY
EXECUTIVE SUMMARY 5
SUMMARY TABLE WORLDWIDE REVENUE OF AUTACOIDS AND RELATED PRODUCTS, THROUGH 2015 ($ BILLIONS) 6
SUMMARY FIGURE WORLDWIDE REVENUE OF AUTACOIDS AND RELATED PRODUCTS, 2008-2015 ($ BILLIONS) 6
Chapter-3: OVERVIEW
DEFINITION 7
GENERAL CHARACTERISTICS OF AUTACOIDS 7
CLASSIFICATION OF AUTACOIDS 7
BIOGENIC AMINE 8
Histamine 8
Roles/ Functions of Histamine 9
Serotonin 10
Roles of Serotonin 10
Catecholamines 11
Functions of Catecholamine 12
POLYPEPTIDE AUTACOIDS 13
Angiotensin 14
Functions of Angiotensin 14
Kinins 15
Functions of Kinins 15
Vasoactive Intestinal Polypeptide 16
Functions of Vasoactive Intestinal Polypeptide 16
Natriuretic Peptides 17
Functions of Natriuretic Peptides 17
ENDOTHELIUM-DERIVED AUTACOIDS 18
Endothelins 18
Functions of Endothelins 19
Nitric Oxide 19
Functions of Nitric Oxide 19
LIPID-DERIVED AUTACOIDS 20
Eicosanoids 20
Functions of Eicosanoids 21
Platelet Activating Factor 22
Functions of Platelet-Activating Factor 22
Chapter-4: DRUGS RELATED TO AUTACOIDS
FIGURE 1 CLASSIFICATION OF DRUGS RELATED TO AUTACOIDS 23
BIOGENIC AMINES 24
HISTAMINE DRUGS 24
H1 Receptor Antagonists 24
TABLE 1 H1 RECEPTOR ANATAGONISTS 25
H2 Antagonists 26
TABLE 2 H2 RECEPTOR ANATAGONISTS 26
H3 and H4 Receptor Antagonists 26
SEROTONIN DRUGS 27
Serotonin-Norepinephrine Reuptake Inhibitors 27
TABLE 3 SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS 28
Selective Serotonin Reuptake Inhibitors (SSRIs) 28
TABLE 4 SELECTIVE SEROTONIN REUPTAKE INHIBITORS 29
Serotonin-Norepinephrine-Dopamine Reuptake Inhibitors 29
Serotonin Receptor Agonists 30
TABLE 5 SEROTONIN RECEPTOR AGONISTS 30
Serotonin Receptor Antagonists 30
TABLE 6 SEROTONIN RECEPTOR ANTAGONISTS 31
CATECHOLAMINES 31
Directly Acting Sympathomimetic Drugs 32
TABLE 7 DIRECTLY ACTING SYMPATHOMIMETIC DRUGS 32
TABLE 7 (CONTINUED) 33
Indirectly Acting Sympathomimetic Drugs 34
TABLE 8 INDIRECTLY ACTING SYMPATHOMIMETIC DRUGS 34
Adrenolytics 35
TABLE 9 ADRENOLYTICS 35
Dopaminergic Antagonists/Dopamine Receptor Antagonists 36
TABLE 10 DOPAMINE ANTAGONISTS 36
POLYPEPTIDE AUTACOIDS 37
ANGIOTENSIN DRUGS 37
Angiotensin II Receptor Antagonists 37
TABLE 11 ANGIOTENSIN II RECEPTOR ANTAGONISTS 38
Angiotensin-Converting Enzymes (ACE) Inhibitors 38
TABLE 12 ANGIOTENSIN CONVERTING ENZYME INHIBITORS 38
KININS 39
DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDE 39
TABLE 13 DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDE 40
DRUGS RELATED TO ENDOTHELIUM-DERIVED AUTACOIDS 40
ENDOTHELIN RECEPTOR ANTAGONISTS 40
TABLE 14 ENDOTHELIN RECEPTOR ANTAGONISTS 40
NITRIC OXIDE 40
TABLE 15 PHARMACEUTICAL ANALOGUES OF NITRIC OXIDE 41
DRUGS RELATED TO LIPID-DERIVED AUTACOIDS 41
EICOSANOID DRUGS 41
TABLE 16 EICOSANOID, EICOSANOID ANALOGS AND RECEPTOR AGONISTS/ANTAGONISTS 42
TABLE 16 (CONTINUED) 43
PLATELET-ACTIVATING FACTOR 43
TABLE 17 PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS 43
Chapter-5: REGULATORY ASPECTS
APPROVALS OF DRUGS RELATED TO AUTACOIDS 44
TABLE 18 NEW AND GENERIC DRUG APPROVALS OF THE DRUGS RELATED TO AUTACOIDS, 2006-2009 44
TABLE 18 (CONTINUED) 45
TABLE 18 (CONTINUED) 46
TABLE 18 (CONTINUED) 47
TABLE 18 (CONTINUED) 48
TABLE 19 NEW DRUG APPLICATIONS OF THE DRUGS RELATED TO AUTACOIDS 49
TABLE 19 (CONTINUED) 50
TABLE 20 SAFETY ALERTS, 2006-2009 50
Chapter-6: INDUSTRY STRUCTURE
MARKET LEADERS WITH THEIR PRODUCTS IN BIOGENIC AMINES 51
TABLE 21 LEADING MANUFACTURERS/SUPPLIERS OF H1 RECEPTOR ANTAGONISTS 51
TABLE 22 LEADING MANUFACTURERS/SUPPLIERS OF H2 RECEPTOR ANTAGONISTS 51
TABLE 23 LEADING MANUFACTURERS/SUPPLIERS OF SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS 52
TABLE 24 LEADING MANUFACTURERS/SUPPLIERS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS 52
TABLE 25 LEADING MANUFACTURERS/SUPPLIERS OF SEROTONIN RECEPTOR AGONISTS 52
TABLE 26 LEADING MANUFACTURERS/SUPPLIERS OF SEROTONIN RECEPTOR ANTAGONISTS 53
TABLE 27 LEADING MANUFACTURERS/SUPPLIERS OF DIRECTLY ACTING SYMPATHOMIMETIC DRUGS 53
TABLE 28 LEADING MANUFACTURERS/SUPPLIERS OF INDIRECTLY ACTING SYMPATHOMIMETIC DRUGS 54
TABLE 29 LEADING MANUFACTURERS/SUPPLIERS OF ADRENOLYTICS 54
TABLE 30 LEADING MANUFACTURERS/SUPPLIERS OF DOPAMINE ANTAGONISTS 54
MARKET LEADERS WITH THEIR PRODUCTS IN POLYPEPTIDE AUTACOIDS 55
TABLE 31 LEADING MANUFACTURERS/SUPPLIERS OF ANGIOTENSIN II RECEPTOR ANTAGONISTS 55
TABLE 32 LEADING MANUFACTURERS/SUPPLIERS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 55
TABLE 33 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDE 56
MARKET LEADERS WITH THEIR PRODUCTS IN ENDOTHELIUM DERIVED AUTACOIDS 56
TABLE 34 LEADING MANUFACTURERS/SUPPLIERS OF ENDOTHELIN RECEPTOR ANTAGONISTS 56
TABLE 35 LEADING MANUFACTURERS/SUPPLIERS OF PHARMACEUTICAL ANALOGS OF NITRIC OXIDE MARKET 56
MARKET LEADERS WITH THEIR PRODUCTS IN LIPID DERIVED AUTACOIDS 57
TABLE 36 LEADING MANUFACTURERS/SUPPLIERS OF EICOSANOIDS 57
TABLE 37 LEADING MANUFACTURERS/SUPPLIERS OF PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS 57
MARKET SHARES OF INDUSTRY LEADERS 58
BIOGENIC AMINES 58
H1 Receptor Antagonists 58
TABLE 38 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF H1 RECEPTOR ANTAGONISTS, 2009 (%) 58
FIGURE 2 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF H1 RECEPTOR ANTAGONISTS, 2009 (%) 59
H2 Receptor Antagonists 59
TABLE 39 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF H2 RECEPTOR ANTAGONISTS, 2009 (%) 60
FIGURE 3 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF H2 RECEPTOR ANTAGONISTS, 2009 (%) 60
Serotonin Norepinephrine Reuptake Inhibitors 61
TABLE 40 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2009 (%) 61
FIGURE 4 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2009 (%) 61
Selective Serotonin Reuptake Inhibitors 62
TABLE 41 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2009 (%) 62
FIGURE 5 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2009 (%) 63
Serotonin Receptor Agonists Market 63
TABLE 42 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SEROTONIN RECEPTOR AGONISTS, 2009 (%) 63
FIGURE 6 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SEROTONIN RECEPTOR AGONISTS, 2009 (%) 64
Serotonin Receptor Antagonists Market 64
TABLE 43 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SEROTONIN RECEPTOR ANTAGONISTS, 2009 (%) 65
FIGURE 7 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SEROTONIN RECEPTOR ANTAGONISTS, 2009 (%) 65
Directly Acting Sympathomimetic Drugs 65
TABLE 44 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF DIRECTLY ACTING SYMPATHOMIMETICS, 2009 (%) 66
FIGURE 8 DIRECTLY ACTING SYMPATHOMIMETICS, 2009 (%) 66
Indirectly Acting Sympathomimetic Drugs 67
TABLE 45 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF INDIRECTLY ACTING SYMPATHOMIMETICS, 2009 (%) 67
FIGURE 9 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF INDIRECTLY ACTING SYMPATHOMIMETICS, 2009 (%) 68
Adrenolytics 68
TABLE 46 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ADRENOLYTICS, 2009 (%) 69
FIGURE 10 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ADRENOLYTICS, 2009 (%) 69
Dopamine Antagonists 70
TABLE 47 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF DOPAMINE ANTAGONISTS, 2009 (%) 70
FIGURE 11 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF DOPAMINE ANTAGONISTS, 2009 (%) 70
POLYPEPTIDE AUTACOIDS 71
Angiotensin II Receptor Antagonists 71
TABLE 48 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ANGIOTENSIN II RECEPTOR ANTAGONISTS, 2009 (%) 71
FIGURE 12 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ANGIOTENSIN II RECEPTOR ANTAGONISTS, 2009 (%) 72
Angiotensin-Converting Enzyme Inhibitors 72
TABLE 49 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, 2009 (%) 73
FIGURE 13 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, 2009 (%) 73
Drugs Related to Vasoactive Intestinal Polypeptides 74
TABLE 50 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDES, 2009 (%) 74
FIGURE 14 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDES, 2009 (%) 74
ENDOTHELIUM-DERIVED AUTACOIDS 75
Endothelin Receptor Antagonists 75
TABLE 51 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ENDOTHELIN RECEPTOR ANTAGONISTS, 2009 (%) 75
FIGURE 15 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ENDOTHELIN RECEPTOR ANTAGONISTS, 2009 (%) 75
Pharmaceutical Analogues of Nitric Oxide 76
TABLE 52 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PHARMACEUTICAL ANALOGUES OF NITRIC OXIDE, 2009 (%) 76
FIGURE 16 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PHARMACEUTICAL ANALOGUES OF NITRIC OXIDE, 2009 (%) 76
LIPID-DERIVED AUTACOIDS 77
Eicosanoids 77
TABLE 53 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF EICOSANOIDS, 2009 (%) 77
FIGURE 17 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF EICOSANOIDS, 2009 (%) 78
Platelet Activating Factor Receptor Antagonists 78
TABLE 54 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS, 2009 (%) 78
FIGURE 18 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS, 2009 (%) 79
Chapter-7: NEW DEVELOPMENTS
TABLE 55 NEW DEVELOPMENTS IN THE FIELD OF HISTAMINE ANTAGONISTS 80
TABLE 56 NEW DEVELOPMENTS IN THE FIELD OF SEROTONIN ANTAGONISTS 81
TABLE 56 (CONTINUED) 82
TABLE 56 (CONTINUED) 83
TABLE 57 NEW DEVELOPMENTS IN THE FIELD OF DOPAMINE AGONISTS 83
TABLE 58 NEW DEVELOPMENTS IN THE FIELD OF ADRENERGIC AGONISTS 84
TABLE 59 NEW DEVELOPMENTS IN THE FIELD OF ADRENOLYTICS 85
TABLE 59 (CONTINUED) 86
TABLE 60 NEW DEVELOPMENTS IN THE FIELD OF DOPAMINE ANTAGONISTS 87
TABLE 60 (CONTINUED) 88
TABLE 61 NEW DEVELOPMENTS IN THE FIELD OF ACE INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS 88
TABLE 61 (CONTINUED) 89
TABLE 62 NEW DEVELOPMENTS IN THE FIELD OF VASOACTIVE INTESTINAL POLYPEPTIDE INHIBITORS 89
TABLE 62 (CONTINUED) 90
TABLE 63 NEW DEVELOPMENTS IN THE FIELD OF ENDOTHELIN ANTAGONISTS 90
TABLE 64 NEW DEVELOPMENTS IN THE FIELD OF EICOSANOIDS 91
TABLE 64 (CONTINUED) 92
Chapter-8: MARKET ANALYSIS
TABLE 65 WORLDWIDE MARKET FOR AUTACOIDS BY REGION, THROUGH 2015 ($ BILLIONS) 93
FIGURE 19 WORLDWIDE MARKET FOR AUTACOIDS BY REGION, 2008-2015 ($ BILLIONS) 94
MARKET SHARES OF AUTACOIDS MARKET, BY REGION 94
TABLE 66 WORLDWIDE AUTACOIDS MARKET SHARES BY REGION, 2009 (%) 95
FIGURE 20 WORLDWIDE AUTACOIDS MARKET SHARES BY REGION, 2009 (%) 95
DRUGS RELATED TO BIOGENIC AMINES 95
TABLE 67 WORLDWIDE MARKET FOR BIOGENIC AMINES, THROUGH 2015 ($ MILLIONS) 96
FIGURE 21 WORLDWIDE MARKET FOR BIOGENIC AMINES, 2008-2015 ($ MILLIONS) 96
HISTAMINES 97
TABLE 68 WORLDWIDE MARKET FOR DRUGS RELATED TO HISTAMINES, THROUGH 2015 ($ MILLIONS) 97
FIGURE 22 WORLDWIDE MARKET FOR DRUGS RELATED TO HISTAMINES, 2008-2015 ($ MILLIONS) 97
H1 and H2 Receptor Anatagonist 98
Market Overview 98
Market Revenue 98
TABLE 69 WORLDWIDE MARKET FOR H1 RECEPTOR ANTAGONISTS, THROUGH 2015 ($ MILLIONS) 99
FIGURE 23 WORLDWIDE MARKET FOR H1 RECEPTOR ANATAGONISTS, 2008-2015 ($ MILLIONS 99
TABLE 70 WORLDWIDE MARKET FOR H2 RECEPTOR ANTAGONISTS, THROUGH 2015 ($ MILLIONS) 100
FIGURE 24 WORLDWIDE MARKET FOR H2 RECEPTOR ANATAGONISTS, 2008-2015 ($ MILLIONS) 100
SEROTONINS 101
TABLE 71 WORLDWIDE MARKET FOR DRUGS RELATED TO SEROTONINS, THROUGH 2015 ($ MILLIONS) 101
FIGURE 25 WORLDWIDE MARKET FOR DRUGS RELATED TO SEROTONINS, 2008-2015 ($ MILLIONS) 102
Serotonin Norepinephrine Reuptake Inhibitors 102
Market Overview 102
Market Revenue 103
TABLE 72 WORLDWIDE MARKET FOR SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, THROUGH 2015 ($ MILLIONS) 104
FIGURE 26 WORLDWIDE MARKET FOR SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2008-2015 ($ MILLIONS) 104
Serotonin Reuptake Inhibitors 105
Market Overview 105
Market Revenue 105
TABLE 73 WORLDWIDE MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITORS, THROUGH 2015 ($ MILLIONS) 106
FIGURE 27 WORLDWIDE MARKET FOR SEROTONIN REUPTAKE INHIBITORS, 2008-2015 ($ MILLIONS) 106
Serotonin Receptor Agonists 107
Market Overview 107
Market Revenue 107
TABLE 74 WORLDWIDE MARKET FOR SELECTIVE SEROTONIN RECEPTOR AGONISTS, THROUGH 2015 ($ MILLIONS) 108
FIGURE 28 WORLDWIDE MARKET FOR SELECTIVE SEROTONIN RECEPTOR AGONISTS, 2008-2015 ($ MILLIONS) 108
Serotonin Receptor Antagonists 109
Market Overview 109
Market Revenue 109
TABLE 75 WORLDWIDE MARKET FOR SELECTIVE SEROTONIN RECEPTOR ANTAGONISTS, THROUGH 2015 ($ MILLIONS) 110
FIGURE 29 WORLDWIDE MARKET FOR SELECTIVE SEROTONIN RECEPTOR ANTAGONISTS, 2008-2015 ($ MILLIONS) 110
CATECHOLAMINE DRUGS 110
TABLE 76 WORLDWIDE MARKET FOR DRUGS RELATED TO CATECHOLAMINES, THROUGH 2015 ($ MILLIONS) 111
FIGURE 30 WORLDWIDE MARKET FOR DRUGS RELATED TO CATECHOLAMINES, 2008- 2015 ($ MILLIONS) 111
Directly Acting Sympathomimetic Drugs 112
Market Overview 112
Market Revenue 112
TABLE 77 WORLDWIDE MARKET FOR DIRECTLY ACTING SYMPATHOMIMETIC DRUGS, THROUGH 2015 ($ MILLIONS) 113
FIGURE 31 WORLDWIDE MARKET FOR DIRECTLY ACTING SYMPATHOMIMETIC DRUGS, 2008-2015 ($ MILLIONS) 113
Indirectly Acting Sympathomimetic Drugs 114
Market Overview 114
Market Revenue 115
TABLE 78 WORLDWIDE MARKET FOR INDIRECTLY ACTING SYMPATHOMIMETIC DRUGS, THROUGH 2015 ($ MILLIONS) 116
FIGURE 32 WORLDWIDE MARKET FOR INDIRECTLY ACTING SYMPATHOMIMETIC DRUGS, 2008-2015 ($ MILLIONS) 116
Adrenolytics 117
Market Overview 117
Market Revenue 117
TABLE 79 WORLDWIDE MARKET FOR ADRENOLYTICS, THROUGH 2015 ($ MILLIONS) 118
FIGURE 33 WORLDWIDE MARKET FOR ADRENOLYTIC, 2008-2015 ($ MILLIONS) 118
Dopamine Antagonists 118
Market Overview 118
Market Revenue 119
TABLE 80 WORLDWIDE MARKET FOR DOPAMINE ANTAGONISTS, THROUGH 2015 ($ MILLIONS) 119
FIGURE 34 WORLDWIDE MARKET FOR DOPAMINE ANTAGONISTS, 2008-2015 ($ MILLIONS) 120
DRUGS RELATED TO POLYPEPTIDE AUTACOIDS 120
TABLE 81 WORLDWIDE MARKET FOR DRUGS RELATED TO POLYPEPTIDE AUTACOIDS, THROUGH 2015 ($ MILLIONS) 121
FIGURE 35 WORLDWIDE MARKET FOR DRUGS RELATED TO POLYPEPTIDE AUTACOIDS, 2008-2015 ($ MILLIONS) 121
ANGIOTENSIN DRUGS 122
TABLE 82 WORLDWIDE MARKET FOR ANGIOTENSIN DRUGS, THROUGH 2015 ($ MILLIONS) 122
FIGURE 36 WORLDWIDE MARKET FOR ANGIOTENSIN DRUGS, 2008-2015 ($ MILLIONS) 122
Angiotensin II Receptor Antagonists 123
Market Overview 123
Market Revenue 124
TABLE 83 WORLDWIDE MARKET FOR ANGIOTENSIN II RECEPTOR ANTAGONISTS, THROUGH 2015 ($ MILLIONS) 124
FIGURE 37 WORLDWIDE MARKET FOR ANGIOTENSIN II RECEPTOR ANTAGONISTS, 2008-2015 ($ MILLIONS) 124
Angiotensin-Converting Enzyme (ACE) Inhibitors 125
Market Overview 125
Market Revenue 125
TABLE 84 WORLDWIDE MARKET FOR ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, THROUGH 2015 ($ MILLIONS) 126
FIGURE 38 WORLDWIDE MARKET FOR ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, 2008-2015 ($ MILLIONS) 126
VASOACTIVE INTESTINAL POLYPEPTIDE 127
Market Overview 127
Market Revenue 127
TABLE 85 WORLDWIDE MARKET FOR DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDES, THROUGH 2015 ($ MILLIONS) 127
FIGURE 39 WORLDWIDE MARKET FOR DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDES, 2008-2015 ($ MILLIONS) 128
ENDOTHELIUM-DERIVED AUTACOIDS 128
TABLE 86 WORLDWIDE MARKET FOR ENDOTHELIUM-DERIVED AUTACOIDS, THROUGH 2015 ($ MILLIONS) 128
FIGURE 40 WORLDWIDE MARKET FOR ENDOTHELIUM-DERIVED AUTACOIDS, 2008-2015 ($ MILLIONS) 129
ENDOTHELIN RECEPTOR ANTAGONISTS 129
Market Overview 129
Market Revenue 130
TABLE 87 WORLDWIDE MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2015 ($ MILLIONS) 130
FIGURE 41 WORLDWIDE MARKET FOR FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2008-2015 ($ MILLIONS) 131
NITRIC OXIDE 131
Market Revenue 131
TABLE 88 WORLDWIDE MARKET FOR NITRIC OXIDE, THROUGH 2015 ($ MILLIONS) 132
FIGURE 42 WORLDWIDE MARKET FOR FOR NITRIC OXIDE, 2008-2015 ($ MILLIONS) 132
DRUGS RELATED TO LIPID-DERIVED AUTACOIDS 132
TABLE 89 WORLDWIDE MARKET FOR LIPID-DERIVED AUTACOIDS, THROUGH 2015 ($ MILLIONS) 133
FIGURE 43 WORLDWIDE MARKET FOR LIPID-DERIVED AUTACOIDS, 2008-2015 ($ MILLIONS) 133
EICOSANOIDS 134
Market Overview 134
Market Revenue 134
TABLE 90 WORLDWIDE MARKET FOR DRUGS RELATED TO EICOSANOIDS, THROUGH 2015 ($ MILLIONS) 135
FIGURE 44 WORLDWIDE MARKET FOR DRUGS RELATED TO EICOSANOIDS, 2008-2015 ($ MILLIONS) 135
PLATELET-ACTIVATING FACTOR (PAF) RECEPTOR ANTAGONISTS 136
Market Overview 136
Market Revenue 136
TABLE 91 WORLDWIDE MARKET FOR PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS, THROUGH 2015 ($ MILLIONS) 137
FIGURE 45 WORLDWIDE MARKET FOR PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS, 2008-2015 ($ MILLIONS) 137
MARKET SHARES OF AUTACOIDS MARKET, BY TYPE 138
TABLE 92 WORLDWIDE AUTACOIDS MARKET SHARES BY TYPE, 2009 (%) 138
FIGURE 46 WORLDWIDE AUTACOIDS MARKET SHARES BY TYPE, 2009 (%) 138
Chapter-9: MARKET BY APPLICATIONS
MARKET SHARE OF APPLICATIONS 139
TABLE 93 SHARE OF VARIOUS SECTORS IN AUTACOIDS-RELATED DRUGS, 2009 (%) 140
FIGURE 47 SHARE OF VARIOUS SECTORS IN AUTACOIDS-RELATED DRUGS, 2009 140
RESPIRATORY DISEASES 140
MARKET REVENUE 141
TABLE 94 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN RESPIRATORY DISEASES, THROUGH 2015 ($ MILLIONS) 142
FIGURE 48 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN RESPIRATORY DISEASES, 2008-2015 ($ MILLIONS) 142
TABLE 95 SALES OF TOP-SELLING RESPIRATORY DRUGS, 2009 (%) 143
CARDIOVASCULAR DISEASES 143
MARKET REVENUE 143
TABLE 96 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN CARDIOVASCULAR DISEASES, THROUGH 2015 ($ MILLIONS) 144
FIGURE 49 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN CARDIOVASCULAR DISEASES, 2008-2015 ($ MILLIONS) 145
TABLE 97 SALES OF TOP-SELLING CARDIOVASCULAR DRUGS, 2009 (%) 145
CENTRAL NERVOUS SYSTEM DISEASES 146
MARKET REVENUE 146
TABLE 98 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN CENTRAL NERVOUS SYSTEM DISEASES, THROUGH 2015 ($ MILLIONS) 147
FIGURE 50 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN CENTRAL NERVOUS SYSTEM, 2008-2015 ($ MILLIONS) 147
TABLE 99 TOP-SELLING CENTRAL NERVOUS SYSTEM DRUGS IN THE ORDER OF SALES, 2009 148
GASTROINTESTINAL DISORDERS 148
MARKET REVENUE 148
TABLE 100 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN GASTROINTESTINAL DISEASES, THROUGH 2015 ($ MILLIONS) 149
FIGURE 51 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN GASTROINTESTINAL DISEASES, THROUGH 2015 ($ MILLIONS) 149
TABLE 101 TOP-SELLING GASTROINTESTINAL DRUGS IN THE ORDER OF THEIR SALES, 2009 150
ANTIEMETICS 150
MARKET REVENUE 150
TABLE 102 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED AS ANTIEMETICS, THROUGH 2015 ($ MILLIONS) 151
FIGURE 52 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED AS ANTIEMETICS, THROUGH 2015 ($ MILLIONS) 151
TABLE 103 TOP-SELLING ANTIEMETICS IN THE ORDER OF THEIR SALES, 2009 152
ANALGESICS 152
MARKET REVENUE 152
TABLE 104 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED AS ANALGESICS, THROUGH 2015 ($ MILLIONS) 153
FIGURE 53 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED AS ANALGESICS, 2008-2015 ($ MILLIONS) 153
OPHTHALMIC 154
MARKET REVENUE 154
TABLE 105 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED IN OPHTHALMIC DISEASES, THROUGH 2015 ($ MILLIONS) 154
FIGURE 54 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED IN OPHTHALMIC DISEASES, 2008-2015 ($ MILLIONS) 155
TABLE 106 TOP-SELLING OPHTHALMIC DRUGS IN THE ORDER OF SALES, 2009 155
OTHERS 156
MARKET REVENUE 156
TABLE 107 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED TO TREAT OTHER DISEASES, THROUGH 2015 ($ MILLIONS) 156
FIGURE 55 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED TO TREAT OTHER DISEASES, THROUGH 2015 ($ MILLIONS) 157
Chapter-10: PATENT ANALYSIS
PATENTS BY YEAR 158
TABLE 108 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2006-2010 (FEB.) 159
FIGURE 56 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2006-2010 (FEB.) 160
FIGURE 57 NUMBER OF PATENTS BY YEAR, 2006-2010 (FEB.) 160
FIGURE 57 (CONTINUED) 161
PATENTS BY TECHNOLOGY 161
TABLE 109 PATENTS BY TECHNOLOGY, 2006-2010 (FEB.) 161
FIGURE 58 PATENTS BY TECHNOLOGY, 2006-2010 (FEB.) 162
PATENTS BY TYPE 162
BIOGENIC AMINES 162
TABLE 110 PATENTS FOR BIOGENIC AMINES, 2006-2010 (FEB.) 162
FIGURE 59 PATENTS FOR BIOGENIC AMINES, 2006-2010 (FEB.) 163
POLYPEPTIDE AUTACOIDS 163
TABLE 111 PATENTS FOR POLYPEPTIDE AUTACOIDS, 2006-2010 (FEB.) 163
FIGURE 60 PATENTS FOR POLYPEPTIDE AUTACOIDS, 2006-2010 (FEB.) 164
LIPID-DERIVED AUTACOIDS 164
TABLE 112 PATENTS FOR LIPID-DERIVED AUTACOIDS, 2006-2010 (FEB.) 164
FIGURE 61 PATENTS FOR LIPID-DERIVED AUTACOIDS, 2006-2010 (FEB.) 165
ENDOTHELIUM-DERIVED AUTACOIDS 165
TABLE 113 PATENTS FOR ENDOTHELIUM-DERIVED AUTACOIDS, 2006-2010 (FEB.) 165
FIGURE 62 PATENTS FOR ENDOTHELIUM-DERIVED AUTACOIDS, 2006-2010 (FEB.) 166
PATENTS BY COMPANY 166
HISTAMINES 166
TABLE 114 NUMBER OF U.S. PATENTS BY COMPANY FOR HISTAMINES, 2006-2010 (FEB.) 167
FIGURE 63 NUMBER OF U.S. PATENTS BY COMPANY FOR HISTAMINES, 2006-2010 (FEB.) 168
SEROTONINS 168
TABLE 115 NUMBER OF U.S. PATENTS BY COMPANY FOR SEROTONINS, 2006-2010 (FEB.) 169
FIGURE 64 NUMBER OF U.S. PATENTS BY COMPANY FOR SEROTONINS, 2006-20100 (FEB.) 169
CATECHOLAMINES 170
TABLE 116 NUMBER OF U.S. PATENTS BY COMPANY FOR CATECHOLAMINES, 2006-2010 (FEB.) 170
FIGURE 65 NUMBER OF U.S. PATENTS BY COMPANY FOR CATECHOLAMINES, 2006-2010 (FEB.) 171
ACE INHIBITORS 171
TABLE 117 NUMBER OF U.S. PATENTS BY COMPANY FOR ACE INHIBITORS, 2006-2010 (FEB.) 171
FIGURE 66 NUMBER OF U.S. PATENTS BY COMPANY FOR ACE INHIBITORS, 2006-20100 (FEB.) 172
ANGIOTENSIN RECEPTOR BLOCKERS 172
TABLE 118 NUMBER OF U.S. PATENTS BY COMPANY FOR ANGIOTENSIN RECEPTOR BLOCKERS, 2006-2010 (FEB.) 172
FIGURE 67 NUMBER OF U.S. PATENTS BY COMPANY FOR ANGIOTENSIN RECEPTOR BLOCKERS, 2006-20100 (FEB.) 173
VASOACTIVE INTESTINAL POLYPEPTIDES 173
TABLE 119 NUMBER OF U.S. PATENTS BY COMPANY FOR VASOACTIVE INTESTINAL POLYPEPTIDES, 2006-2010 (FEB.) 173
FIGURE 68 NUMBER OF U.S. PATENTS BY COMPANY FOR VASOACTIVE INTESTINAL POLYPEPTIDES, 2006-20100 (FEB.) 174
PLATELET-ACTIVATING FACTOR INHIBITORS 174
TABLE 120 NUMBER OF U.S. PATENTS BY COMPANY FOR PLATELET-ACTIVATING FACTOR INHIBITORS, 2006-2010 (FEB.) 174
EICOSANOIDS 174
TABLE 121 NUMBER OF U.S. PATENTS BY COMPANY FOR EICOSANOIDS, 2006-2010 (FEB.) 175
FIGURE 69 NUMBER OF U.S. PATENTS BY COMPANY FOR EICOSANOIDS, 2006-2010 (FEB.) 176
ENDOTHELIN RECEPTOR ANTAGONISTS 176
TABLE 122 NUMBER OF U.S. PATENTS BY COMPANY FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2006-2010 (FEB.) 177
FIGURE 70 NUMBER OF U.S. PATENTS BY COMPANY FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2006-2010 (FEB.) 177
PATENTS BY COUNTRY 177
HISTAMINES 177
TABLE 123 NUMBER OF U.S. PATENTS BY COUNTRY FOR HISTAMINES, 2006-2010 (FEB.) 178
FIGURE 71 NUMBER OF U.S. PATENTS BY COUNTRY FOR HISTAMINES, 2006-2010 (FEB.) 178
SEROTONINS 178
TABLE 124 NUMBER OF U.S. PATENTS BY COUNTRY FOR SEROTONINS, 2006-2010 (FEB.) 179
FIGURE 72 NUMBER OF U.S. PATENTS BY COUNTRY FOR SEROTONINS, 2006-2010 (FEB.) 179
CATECHOLAMINES 180
TABLE 125 NUMBER OF U.S. PATENTS BY COUNTRY FOR CATECHOLAMINES, 2006-2010 (FEB.) 180
FIGURE 73 NUMBER OF U.S. PATENTS BY COUNTRY FOR CATECHOLAMINES, 2006-2010 (FEB.) 181
ANGIOTENSIN II RECEPTOR BLOCKERS 181
TABLE 126 NUMBER OF U.S. PATENTS BY COUNTRY FOR ANGIOTENSIN II RECEPTOR BLOCKERS, 2006-2010 (FEB.) 181
FIGURE 74 NUMBER OF U.S. PATENTS BY COUNTRY FOR ANGIOTENSIN II RECEPTOR BLOCKERS, 2006-2010 (FEB.) 182
ACE INHIBITORS 182
TABLE 127 NUMBER OF U.S. PATENTS BY COUNTRY FOR ACE INHIBITORS, 2006-2010 (FEB.) 182
FIGURE 75 NUMBER OF U.S. PATENTS BY COUNTRY FOR ACE INHIBITORS, 2006-2010 (FEB.) 183
VASOACTIVE INTESTINAL POLYPEPTIDES 183
TABLE 128 NUMBER OF U.S. PATENTS BY COUNTRY FOR VASOACTIVE INTESTINAL POLYPEPTIDES, 2006-2010 (FEB.) 183
FIGURE 76 NUMBER OF U.S. PATENTS BY COUNTRY FOR VASOACTIVE INTESTINAL POLYPEPTIDES, 2006-2010 (FEB.) 184
PLATELET-ACTIVATING FACTOR INHIBITORS 184
TABLE 129 NUMBER OF U.S. PATENTS BY COUNTRY FOR PLATELET-ACTIVATING FACTOR INHIBITORS, 2006-2010 (FEB.) 184
FIGURE 77 NUMBER OF U.S. PATENTS BY COUNTRY FOR PLATELET-ACTIVATING FACTOR INHIBITORS, 2006-2010 (FEB.) 185
EICOSANOIDS 185
TABLE 130 NUMBER OF U.S. PATENTS BY COUNTRY FOR EICOSANOIDS, 2006-2010 (FEB.) 186
FIGURE 78 NUMBER OF U.S. PATENTS BY COUNTRY FOR EICOSANOIDS, 2006-2010 (FEB.) 186
ENDOTHELIN RECEPTOR ANTAGONISTS 187
TABLE 131 NUMBER OF U.S. PATENTS BY COUNTRY FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2006-2010 (FEB.) 187
FIGURE 79 NUMBER OF U.S. PATENTS BY COUNTRY FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2006-2010 (FEB.) 187
PATENTS BY ASSIGNEE 188
HISTAMINES 188
TABLE 132 PATENTS BY ASSIGNEE FOR HISTAMINES, 2006-2010 (FEB.) 188
FIGURE 80 PATENTS BY ASSIGNEE FOR HISTAMINES, 2006-2010 (FEB.) 188
SEROTONINS 189
TABLE 133 PATENTS BY ASSIGNEE FOR SEROTONINS, 2006-2010 (FEB.) 189
FIGURE 81 PATENTS BY ASSIGNEE FOR SEROTONINS, 2006-2010 (FEB.) 189
CATECHOLAMINES 190
TABLE 134 PATENTS BY ASSIGNEE FOR CATECHOLAMINES, 2006-2010 (FEB.) 190
FIGURE 82 PATENTS BY ASSIGNEE FOR CATECHOLAMINES, 2006-2010 (FEB.) 190
ACE INHIBITORS 191
TABLE 135 PATENTS BY ASSIGNEE FOR ACE INHIBITORS, 2006-2010 (FEB.) 191
FIGURE 83 PATENTS BY ASSIGNEE FOR ACE INHIBITORS, 2006-2010 (FEB.) 191
ANGIOTENSIN RECEPTOR BLOCKERS 192
TABLE 136 PATENTS BY ASSIGNEE FOR ANGIOTENSIN RECEPTOR BLOCKERS, 2006-2010 (FEB.) 192
FIGURE 84 PATENTS BY ASSIGNEE FOR ANGIOTENSIN RECEPTOR BLOCKERS, 2006-2010 (FEB.) 192
VASOACTIVE INTESTINAL POLYPEPTIDES 193
TABLE 137 PATENTS BY ASSIGNEE FOR VASOACTIVE INTESTINAL POLYPEPTIDES, 2006-2010 (FEB.) 193
FIGURE 85 PATENTS BY ASSIGNEE FOR VASOACTIVE INTESTINAL POLYPEPTIDES, 2006-2010 (FEB.) 193
PLATELET-ACTIVATING FACTOR INHIBITORS 194
TABLE 138 PATENTS BY ASSIGNEE FOR PLATELET-ACTIVATING FACTOR INHIBITORS, 2006-2010 (FEB.) 194
FIGURE 86 PATENTS BY ASSIGNEE FOR PLATELET-ACTIVATING FACTOR INHIBITORS, 2006-2010 (FEB.) 194
EICOSANOIDS 195
TABLE 139 PATENTS BY ASSIGNEE FOR EICOSANOIDS, 2006-2010 (FEB.) 195
FIGURE 87 PATENTS BY ASSIGNEE FOR EICASANOIDS, 2006-2010 (FEB.) 195
ENDOTHELIN RECEPTOR ANTAGONISTS 196
TABLE 140 PATENTS BY ASSIGNEE FOR ENDOTHELIN RECEPTOR ANATAGONISTS, 2006-2010 (FEB.) 196
FIGURE 88 PATENTS BY ASSIGNEE FOR ENDOTHELIN RECEPTOR ANATAGONISTS, 2006-2010 (FEB.) 196
Chapter-11: CURRENT SITUATION OF AUTACOID-RELATED DRUGS
FACTS ABOUT AUTACOID-RELATED DRUGS 197
FACTORS AFFECTING THE SALES OF AUTACOID-RELATED DRUGS 198
COMPETITION 198
COST 198
PATENT EXPIRATIONS 199
TABLE 141 PATENT EXPIRATIONS 200
MAJOR FACTORS FOR FUTURE GROWTH 200
LIFE EXPECTANCY 200
PATENT PROTECTION 201
DRUGS PORTFOLIO MANAGEMENT 201
STRATEGIES OF PHARMACEUTICAL COMPANIES 201
PATENT EXTENSIONS 201
MERGERS, ACQUISITIONS AND COLLABORATIONS 202
PRESCRIPTION TO OVER-THE-COUNTER SWITCHING 202
DIRECT-TO-CONSUMER ADVERTISING 203
APPEAL FOR GENERIC DRUG MANUFACTURING 203
Chapter-12: COMPANY PROFILES
ABBOTT LABORATORIES 204
ACTELION PHARMACEUTICALS LTD. 204
ALCON INC. 205
ALLERGAN INC. 206
APOTEX 206
APP PHARMA 207
ASTRAZENECA PLC 208
AUROBINDO PHARMA 209
BAXTER INTERNATIONAL INC. 209
BAYER HEALTHCARE 210
BEDFORD LABORATORIES 210
BIOVAIL CORPORATION 210
BOEHRINGER INGELHEIM 211
BRISTOL-MYERS SQUIBB 212
CHATTEM INC. 212
CIPLA LTD. 213
CYPRESS BIOSCIENCE, INC. 213
DAIICHI SANKYO CO. LTD. 214
DAVA PHARMCEUTICALS INC. 214
DEY PHARMA, L.P. 215
DR. REDDY'S LABORATORIES LIMITED 215
ELI LILLY & CO. 216
FOREST LABORATORIES INC. 217
GILEAD SCIENCES INC. 217
GLAXO SMITH KLINE PLC 218
HELSINN HEALTHCARE S.A. 219
HOSPIRA INC. 220
IPSEN S.A. 220
JAZZ PHARMACEUTICALS INC. 221
JOHNSON & JOHNSON 222
KING PHARMACEUTICALS INC. 222
MERCK & CO. INC. 223
MYLAN LABS 224
NOVARTIS AG 225
NUVO RESEARCH INC. 226
NYCOMED US INC. 226
PAR PHARMACEUTICAL COMPANIES INC. 227
PEDINOL PHARMACAL, INC. 228
PERRIGO COMPANY 228
PFIZER INC. 229
PROSTRAKAN GROUP PLC 229
ROCHE 230
SALIX PHARMACEUTICALS 231
SANDOZ 231
SANOFI- AVENTIS 232
SHIONOGI PHARMA INC. 233
SHIRE PLC 233
SOLVAY PHARMACEUTICALS SA 234
TARO PHARMACEUTICAL INDUSTRIES LTD. 234
TEVA PHARMACEUTICAL INDUSTRIES LIMITED 235
UCB INC. 235
UNITED THERAPEUTICS 236
VALEANT PHARMACEUTICALS INTERNATIONAL 236
VIVUS INC. 236
WATSON PHARMACEUTICALS 237
XANODYNE 238
ZYDUS PHARMA USA 238
APPENDIX I--ABBREVIATIONS AND DEFINITIONS 239
ABBREVIATIONS AND DEFINITIONS 239
ABBREVIATIONS AND DEFINITIONS (CONTINUED) 240
To order this report:
Drug and Medication Industry: Autacoids and Related Drugs: Technologies and Global Markets
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg Reportlinker Email: [email protected] US: (805)652-2626 Intl: +1 805-652-2626
SOURCE Reportlinker
